News Search Results
Aug 12, 2024, 07:00 ET Leap Therapeutics Reports Second Quarter 2024 Financial Results
Mass., Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June
More news about: Leap Therapeutics, Inc.
Aug 12, 2024, 06:40 ET Animal Health Industry to Witness Exponential Growth from 2023 to 2030: Grand View Research, Inc.
gene therapy, stem cell therapy, and immunotherapy are expanding the possibilities for treating previously untreatable conditions. Advances in biotechnology, such as recombinant DNA technology and vector-based vaccines, are leading to the development of more effective and safer vaccines. Increased awareness
More news about: Grand View Research, Inc.
Aug 11, 2024, 23:42 ET German Stem Cell Expert Leads Delegation to Boost Sino-German Health & Educational Cooperation
an earlier Chinese governmental visit to Germany in June, which focused on collaboration in stem cell research, biotechnology, health, and medical education.
More news about: EWBG
Aug 11, 2024, 23:31 ET German Stem Cell Expert Leads Delegation to Boost Sino-German Health & Educational Cooperation
an earlier Chinese governmental visit to Germany in June, which focused on collaboration in stem cell research, biotechnology, health, and medical education.
More news about: EWBG
Aug 09, 2024, 17:30 ET Capillary Electrophoresis Market size is set to grow by USD 308 million from 2024-2028, Increasing R and D expenditure boost the market, Technavio
sequencing to individualized treatment, and is used to analyze DNA, RNA, and protein molecules. The market also caters to various industries, including biotechnology, genomics, and pharmaceuticals, with applications in tobacco use, alcohol use, poor diet, inactivity, air pollution, and DNA analysis for diseases
More news about: Technavio
Aug 09, 2024, 09:00 ET The Galien Foundation Announces 2024 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"
to honoring innovators in life sciences, today announced the 2024 Prix Galien USA Award nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Disease." Winners will be announced during
More news about: The Galien Foundation
Aug 09, 2024, 07:30 ET Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Aug 09, 2024, 01:30 ET AMGEN TO OPEN NEW SITE IN HYDERABAD, INDIA
people and will be operational in Q4 2024. "At a time when a quickly aging global population needs more innovation, the convergence of biotechnology and technology is enabling Amgen to work with greater speed, confidence, and efficiency — an incredibly exciting milestone for which we have been
More news about: Amgen
Aug 08, 2024, 17:15 ET Cochlear Implants Market size is set to grow by USD 975.3 million from 2024-2028, Increasing prevalence of hearing loss boost the market, Technavio
Sonova AG, Starkey Laboratories Inc., The Cochlear Implant Group India, TODOC Co. Ltd., and ZHEJIANG NUROTRON BIOTECHNOLOGY CO. LTD..
More news about: Technavio
Aug 08, 2024, 16:19 ET Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
Aug 08, 2024, 16:15 ET Nektar Therapeutics Reports Second Quarter 2024 Financial Results
information and a PIN allowing them to access the live call. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Aug 08, 2024, 16:05 ET INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
MEETING, Pa., Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Aug 08, 2024, 16:05 ET 10x Genomics Announces Senior Leadership Changes
experience, Moustafa is an accomplished leader with a proven track record of driving commercial success and building high-performance teams in the biotechnology and life sciences industry. Moustafa joined 10x Genomics in April 2022 as Senior Vice President of Commercial Operations
More news about: 10x Genomics, Inc.
Aug 08, 2024, 12:45 ET Catalyst Clinical Research Announces First CCO
ResearchCatalyst Clinical Research, a clinical research organization (CRO), provides highly customizable solutions to the global biopharmaceutical and biotechnology industries through two established solutions:
More news about: Catalyst Clinical Research
Aug 08, 2024, 10:30 ET Label-Free Detection Market worth $747 million by 2029 driven by Technological Advancements | MarketsandMarkets™
Segmentation: Pharmaceutical & Biotechnology Companies Lead The end-user segments include pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), and other users. In 2023, pharmaceutical & biotechnology companies led the market
More news about: MarketsandMarkets
Aug 08, 2024, 10:24 ET Companion Diagnostics Market size is set to grow by USD 28.98 billion from 2024-2028, Rising use of personalized medicine to boost the market growth, Technavio
(ROW)1.1 Life science- The Companion Diagnostics Market is witnessing significant growth due to the increasing need for pharmaceutical and biotechnology companies to develop high-quality, regulatorily compliant drugs and therapeutic treatments. During the drug discovery process, companion diagnostic
More news about: Technavio
Aug 08, 2024, 10:01 ET Collaborative Robots Market to Be Worth $2.9 Billion by 2031 - Exclusive Report by Meticulous Research®
transportation, electrical & electronics, metal & machinery, plastic & chemicals, oil & gas, food & beverage, aerospace & defense, biotechnology, healthcare, and other end-use industries}, and geography. The study also evaluates industry competitors and analyzes the market at the regional
More news about: Meticulous Market Research Pvt. Ltd.
Aug 08, 2024, 09:00 ET Origin Agritech Appoints Patrick Cheng as Chief Financial Officer and Board Director
the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited
Aug 08, 2024, 09:00 ET Traackr Finds Engagement is on the Rise for Beauty Creators and Sponsored Content
35% and 40% respectively. The reign of everything aqua borrows from its connection to the planet, with products utilizing marine technologies and biotechnology to create fun and energetic looks like bright blue nails (+35%) and blue aesthetic grunge (+40%). Consumers are hot for summer, with
More news about: Traackr, Inc.
Aug 08, 2024, 09:00 ET InventWood Raises $8 Million and Appoints Tyler Huggins as CEO as It Prepares For Early 2025 Commercial Launch
than 20 years dedicated to protecting and restoring America's forests and leading sustainable initiatives across environmental engineering and biotechnology, joins InventWood at a pivotal moment as the company begins to scale its pioneering 100% wood facade. As the company prepares for its early
More news about: InventWood Inc.
Aug 08, 2024, 08:00 ET Flamingo Therapeutics Announces First Patients Dosed in the United Kingdom and Korea in Ongoing Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC)
undruggable transcription factors and long non-coding RNAs. Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Abrdn (formerly funds managed by Tekla Capital Management LLC), Andera Partners, Bpifrance Large Venture, Bpifrance through
More news about: Flamingo Therapeutics
Aug 08, 2024, 08:00 ET T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors
Aug. 8, 2024 /PRNewswire/ -- At the prestigious ASCO Breakthrough 2024, T-MAXIMUM PHARMACEUTICAL, a biotechnology company specializing in the development of universal cell-based therapies, received high acclaim from the international medical community for its
More news about: T-MAXIMUM PHARMACEUTICAL
Aug 08, 2024, 07:45 ET Research Bridge Partners Appoints New Members to the Company's Board of Directors
and Immunology, Emerita at Stanford University, and currently serves as a senior vice president in research at Vir Biotechnology, Inc. Her research interests include the molecular virology and pathogenesis of herpesviruses, with a focus on varicella zoster virus, immune responses
More news about: Research Bridge Partners
Aug 08, 2024, 07:05 ET REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
available for approximately 30 days following the presentation. ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development
More news about: REGENXBIO Inc.
Aug 08, 2024, 07:00 ET Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Sulagna
More news about: Nanoscope Therapeutics